A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
Latest Information Update: 27 Oct 2025
At a glance
- Drugs Brenipatide (Primary)
- Indications Alcoholism
- Focus Registrational; Therapeutic Use
- Acronyms RENEW-ALC-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Oct 2025 New trial record